Repligen Corporation (RGEN)
RGEN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/730272/000119312526076528/0001193125-26-076528-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RGEN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 1986 |
| SEC CIK | 0000730272 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $738.3M |
| Net income | $48.9M |
| Operating income | $55.2M |
| Net margin | 6.6% |
| Operating margin | 7.5% |
| Revenue growth | +16.4% |
| Cash | $566.0M |
| Total assets | $2.9B |
| P/E (computed) | 212.8× |
| P/S (computed) | 14.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-30 |
| Cash and burn | $727.0M cash; operating cash flow $32.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 63,923,738 (2026-10-23); 56,290,749 a year earlier; 55,832,013 three years earlier. | Cover page 2026-10-23 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-11 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $14.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $209.3M | -$38.4M | $43.1M | $727.0M | $555.6M | $805.6M | 10-Q 2026-10-30 |
| Q2 2026 2026-06-30 | $204.1M | $5.0M | $32.8M | $606.8M | $551.0M | $785.1M | 10-Q 2026-07-29 |
| Q1 2026 2026-03-31 | $194.3M | $8.3M | $28.3M | $582.6M | $546.6M | $763.3M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $197.9M | $13.3M | $25.7M | $566.0M | $542.2M | $738.3M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $188.8M | $14.9M | $48.1M | $748.7M | $537.9M | $707.9M | 10-Q 2026-10-30 |
| Q2 2025 2025-06-30 | $182.4M | $14.9M | $28.6M | $708.9M | $533.7M | $674.0M | 10-Q 2026-07-29 |
| Q1 2025 2025-03-31 | $169.2M | $5.8M | $15.0M | $697.2M | $529.6M | $650.4M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $167.5M | -$33.9M | $39.2M | $757.4M | $525.6M | $634.4M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-04 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-10-30 |
| Latest current report | 8-K | 2026-11-06 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.3% |
| 1 month | -4.3% |
| 3 months | +0.2% |
| Year to date | +2.4% |
| 1 year | +11.4% |
| From 52-week high | -13.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| QGEN | Qiagen N.V. Common Shares | $49.81 | -0.16% | $10.3B |
| KYMR | Kymera Therapeutics Inc. | $125.85 | -1.35% | $10.7B |
| HALO | Halozyme Therapeutics Inc. | $96.50 | -3.76% | $11.0B |
| PCVX | Vaxcyte Inc. | $61.61 | -2.78% | $9.8B |
| TECH | Bio-Techne Corp | $72.79 | -0.01% | $11.4B |
| KRYS | Krystal Biotech Inc. | $297.90 | -2.40% | $8.8B |
| CGON | CG Oncology Inc. | $84.78 | +13.95% | $7.6B |
| TWST | Twist Bioscience Corporation | $105.04 | -5.88% | $7.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier